Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study
暂无分享,去创建一个
J. Y. Lee | J. W. Lee | T. H. Kim | J. Chung | S. W. Lee | K. Lee | S. Lee | D. Kang | J. Jo | J. Han
[1] C. Roehrborn,et al. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily , 2008, Clinical interventions in aging.
[2] G. Hoke,et al. Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. , 2008, The American journal of medicine.
[3] M. Elhilali,et al. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3‐year experience in real‐life practice , 2008, BJU international.
[4] Y. Miyaji,et al. Natural course of lower urinary tract symptoms following discontinuation of alpha‐1‐adrenergic blockers in patients with benign prostatic hyperplasia , 2007, International journal of urology : official journal of the Japanese Urological Association.
[5] C. Roehrborn. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. , 2007, BJU international.
[6] T. Morita,et al. Discontinuation of Tamsulosin Treatment in Men with Lower Urinary Tract Symptoms: A Pilot Study , 2006, Urologia Internationalis.
[7] M. Elhilali. Alfuzosin: an α1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia , 2006, Expert opinion on pharmacotherapy.
[8] M. Elhilali. Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. , 2006, Expert opinion on pharmacotherapy.
[9] M. Marberger,et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. , 2004, Urology.
[10] Mark Emberton,et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). , 2004, European urology.
[11] H. Lepor. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. , 2004, Reviews in urology.
[12] V. L. Kumar,et al. Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate , 2004, International Urology and Nephrology.
[13] C. Reid,et al. Predictors of normotension on withdrawal of antihypertensive drugs in elderly patients: prospective study in second Australian national blood pressure study cohort , 2002, BMJ : British Medical Journal.
[14] L. Kiemeney,et al. Long-Term Risk Of Re-Treatment Of Patients Using α-Blockers For Lower Urinary Tract Symptoms , 2002 .
[15] K. McKeage,et al. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. , 2002, Drugs.
[16] L. Kiemeney,et al. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. , 2002, The Journal of urology.
[17] M. O'Leary. Tamsulosin: current clinical experience. , 2001, Urology.
[18] H. Lepor,et al. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. , 2001, Urology.
[19] M. Aylett,et al. Stopping drug treatment of hypertension: experience in 18 British general practices. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.
[20] N. Masumori,et al. Epidemiology and Natural History of Benign Prostatic Hyperplasia , 1997, International journal of urology : official journal of the Japanese Urological Association.
[21] D. Peters,et al. Finasteride , 1993, Drugs.
[22] M. Caine. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. , 1990, The Urologic clinics of North America.